23 HATA'AS STREET, KFAR SABA, L3
Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
Material disclosure
Annual Report to Security Holders
Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
Provides Corporate Update and Reports First Quarter 2026 Financial Results
Financial Results, Press Release
Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Post-Effective Amendment to Registration Statement